Clinical TrialApr 17, 2026, 04:02 PM
Adagene's Muzastotug Triple Combo Shows 66.7% ORR in HCC Trial
AI Summary
Adagene Inc. presented new Phase 1b/2 data for muzastotug in triple combination regimens at AACR 2026. In locally advanced or metastatic HCC, the triple combination of muzastotug + atezolizumab + bevacizumab achieved a 66.7% overall response rate (ORR), significantly higher than the 32.5% ORR in the control arm. For late-line MSS CRC, muzastotug combined with pembrolizumab + fruquintinib showed dose-dependent ORRs of 25% and 40%. The data supports muzastotug's ability to improve efficacy without increasing toxicity, leveraging its masking technology.
Key Highlights
- Triple combination of muzastotug + atezolizumab + bevacizumab achieved 66.7% ORR in HCC trial.
- Control arm (atezolizumab + bevacizumab) showed 32.5% ORR in HCC.
- Triple combination of muzastotug + pembrolizumab + fruquintinib had 25% and 40% ORR in MSS CRC.
- Safety profile was consistent with historical studies, with no Grade 4 or 5 treatment-related adverse events.
- Muzastotug in combination with pembrolizumab has FDA Fast Track designation for MSS mCRC.